^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABBV-706
i
Other names: ABBV-706, ABBV706, ABBV 706
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
Topoisomerase I inhibitor, SEZ6-targeted antibody-drug conjugate
Related drugs:
9d
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | N=60 --> 180
Enrollment change • Trial initiation date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
13d
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | N=50 --> 180
Enrollment change • Trial initiation date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
14d
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=50, Recruiting, AbbVie | N=27 --> 50
Enrollment change • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
15d
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | N=27 --> 180
Enrollment change • Trial initiation date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
17d
New P2 trial • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
21d
M24-633: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Participants with Previously Untreated Extensive Stage Small Cell Lung Cancer (2024-517490-24-00)
P1/2, N=18, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
New P1/2 trial • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • ABBV-706
2ms
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=531, Not yet recruiting, AbbVie
New P3 trial • Adverse events
|
topotecan • Zepzelca (lurbinectedin) • ABBV-706 • Calsed (amrubicin)
3ms
Expanded Access to ABBV-706 (clinicaltrials.gov)
P=N/A, N=0, Available, AbbVie
New trial
|
ABBV-706
4ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
Trial completion date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
4ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | Trial completion date: Sep 2031 --> May 2029
Trial completion date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
4ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2
Enrollment open • Phase classification • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
5ms
SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=180, Not yet recruiting, AbbVie | Trial completion date: May 2029 --> Sep 2031
Trial completion date • Adverse events
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
Share via
